Cancer vascular endothelial growth factor (VEGF) promotes new blood

Cancer
cell is similar with normal cell; they both needs blood supply to survive. In
lung cancer,  vascular endothelial growth factor (VEGF)
promotes new blood cell growth which supply nutrients  to cancer cells. Angiogenesis inhibitor such
as Bevacizumab (Avastin) stops tumor growth by blocking VEGF in connecting to
VEGFRI receptor. Preventing VEGF from attaching to
extracellular receptor by utilizing VEGF-specific proteins and binding TKIs to
the outer part of VEGFR are some ways to anti-VEGF solution (Larsen,
J., et al.,2011; Pirker, R., et al., 2016;).

One of the main focus of
research nowadays is related to lung cancer. A group of researcher study on the
effect of serum thyroid stimulating hormone (TSH) levels on prognosis and
survival in NSCLC patients. The study was carried out in 9-year follow up with
a total participant of 30000 with unknown thyroid disease in the start of the
study.  Thyroid hormone have The
hypothesis suggesting that thyroid hormones may also affect the risk of cancer
progression as they have important role in physiological growth, maturation and
metabolism, has been considered in several studies. However, it has not created
a strong statistical effect. The study found out significant statistical difference in
that survival time for participant with reduced TSH and normal TSH is 225 and
385 days, respectively. These results suggest that TSH can be a physiological
factor in both NSCLC carcinogens and progression of the diseases. This is the
first study suggesting that hypothyroidism is an important factor in the
prognosis of late NSCLC, however, it is recommended to conduct more scientific
research to prove this claim. This study may give insights to scientist on
future research for the betterment of lung cancer management (Degirmencioglu, S., et al 2016).

We Will Write a Custom Essay Specifically
For You For Only $13.90/page!


order now

Another ground-breaking
discovery is the introduction of the CAR-T therapy to the public. This therapy
includes extraction of the person’s serum containing the cell’s immune system,
then reprogram and remodel to better act against cancer. The drug is called
Kymriah. This is a significant innovation in the field of medicine since it is
clinically acknowledged that immune system is undeniably effective defence
against cancer.  The therapy is used for
children and people on their mid-20’s who was not treated successfully from the
conventional method of treating cancer. This is a good indicator that cancer
patient will have more contact to advanced technology. Though Kymriah holds a
potential neurological complication (Cytokine release syndrome), medicine (Actemra)
to
counteract this deadly effect is available in the market. The cost is amounting
to $600,000 – $700,000, not everyone will have the fund but in USA, agreement
has been signed that government will shoulder the cost if the patient respond
to the treatment (Cortez, M., et al., 2017).

Conclusion

Targeted
therapies have become the standard approach for lung cancer management. Records
of predictive biomarkers and druggability of genetic mutations are increasing.
However, some targeted treatment is suggested during the course of scientific
experiment. Scientific knowledge of the
molecular basis of lung cancer and in combination of clinical knowledge would
result to better treatment of lung cancer.